HTF Market Intelligence released a new research report of 101 pages on title ‘Frontier Pharma: Alzheimer’s Disease and Associated Indications – Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression’ with detailed analysis, forecast and strategies.
Alzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable disease characterized by loss of memory and other mental abilities. It has a devastating impact on independence and quality of life, with patients requiring full-time care in the later disease stages. In addition to cognitive impairment, AD is associated with behavioral and psychological changes, which often represent the greatest challenges for patients and caregivers.
Request a sample report @ https://www.htfmarketreport.com/sample-report/482110-frontier-pharma-17
The prevalence of AD is escalating rapidly, largely owing to aging populations, as advancing age is the most important epidemiological risk factor for the disease. This will amplify the already substantial societal and economic costs of the disease over the coming years. This has led to high levels of R&D investment over the past two decades, but clinical trial failure rates within the indication are extremely high and treatment options remain limited. There are no disease-modifying therapies for AD, and current approaches can only temporarily slow the worsening of symptoms.
The report focuses on AD alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=482110
Unmet need is extremely high in AD, with behavioral and psychological complications contributing significantly to the disease burden
– What are the most important etiological risk factors and pathophysiological processes implicated in AD?
– What is the current treatment algorithm?
– How common are anxiety, depression, psychosis and insomnia in AD?
The AD pipeline is large and contains a very high proportion of first-in-class product innovation
– Which molecule types and molecular targets are most prominent across AD and its associated indications?
– What are the connections, in terms of first-in-class innovation, between AD and its associated indications?
– Which first-in-class targets are most promising?
– How does the level of first-in-class innovation differ between products in development for anxiety, depression, psychosis and insomnia?
– How does first-in-class target diversity differ by stage of development and molecular target class?
The deals landscape is active and dominated by G-protein coupled receptor (GPCR)-targeting products
– Which indications attract the highest deal values?
– How has deal activity fluctuated over the past decade?
– Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?
Reasons to buy
This report will allow you to –
– Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
– Identify leading products and key unmet needs within the market.
– Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
– Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
– Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.
Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/482110-frontier-pharma-17
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Executive Summary 6
2.1 Limited Treatment Options despite Large Market Opportunity 6
2.2 Exceptionally High Level of First-in-Class Innovation within Alzheimer’s Disease Pipeline 6
2.3 Active Deals Landscape Dominated by GPCR-Targeting Products 6
3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic Products 8
3.2 Diversification of Molecular Targets 8
3.3 Innovative First-in-Class Product Developments Remain Attractive 9
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 9
3.5 Sustained Innovation in Alzheimer’s Disease 10
3.6 GBI Research Report Guidance 10
4 Clinical and Commercial Landscape 12
4.1 Disease Overview 12
4.2 Classification of Dementia and Mild Cognitive Impairment 12
4.3 Symptoms, Disease Staging and Prognosis 13
4.4 Diagnosis 14
4.4.1 Mini Mental State Exam 15
4.4.2 Alzheimer’s Disease Assessment Scale – Cognitive 15
4.4.3 Alzheimer’s Disease Co-operative Study – Activities of Daily Living Inventory 16
4.4.4 Imaging Techniques 16
4.4.5 Lumbar Puncture 17
4.4.6 Blood Tests 17
4.5 Epidemiology 17
4.6 Etiology and Pathophysiology 17
4.6.1 Etiological Risk Factors 17
4.6.2 Pathophysiology 18
4.7 Management and Treatment of Alzheimer’s Disease 21
4.7.1 Pharmacological Intervention 21
4.7.2 Non-pharmacological Intervention 22
4.8 Overview of Marketed Products 23
4.9 Indications Associated with Alzheimer’s Disease 26
4.9.1 Anxiety 26
4.9.2 Depression 27
4.9.3 Psychosis 28
4.9.4 Insomnia 29
5 Assessment of Pipeline Product Innovation 30
5.1 Overview 30
5.2 Pipeline by Stage of Development and Molecule Type 30
5.2.1 Alzheimer’s Disease 30
5.2.2 Alzheimer’s-Disease-Associated Indications 31
5.3 Pipeline by Molecular Target 33
5.3.1 Alzheimer’s Disease 33
5.3.2 Alzheimer’s-Disease-Associated Indications 35
5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 36
5.4.1 Alzheimer’s Disease 36
5.4.2 Alzheimer’s-Disease-Associated Indications 37
5.5 First-in-Class Programs Targeting Novel Molecular Targets 37
5.5.1 Alzheimer’s Disease 37
5.5.2 Alzheimer’s-Disease-Associated Indications 41
5.6 Ratio of First-in-Class Products to First-in-Class Targets 44
5.6.1 Alzheimer’s Disease 44
5.6.2 Alzheimer’s-Disease-Associated Indications 46
5.7 List of All First-in-Class Pipeline Programs 48
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/482110-frontier-pharma-17
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218